Objective: This study aims to study the prognostic impact of left ventricular function on mortality and examine the effect of age on the prognostic value of left ventricular function. Methods: We examined the myocardial ischaemia national audit project registry (2006)(2007)(2008)(2009)(2010) data with a mean followup of 2.1 years. Left ventricular function was categorised into good (ejection fraction ⩾50%), moderate (ejection fraction 30-49%) and poor (ejection fraction <30%) categories. Cox proportional hazards models were constructed to examine the prognostic significance of left ventricular function in different age groups (<65, 65-74, 75-84 and ⩾85 years) on allcause mortality adjusting for baseline variables. Results: Out of 424,848 patients, left ventricular function data were available for 123,609. Multiple imputations were used to impute missing values of left ventricular function and the final sample for analyses was drawn from 414,305. After controlling for confounders, 339,887 participants were included in the regression models. For any age group, mortality was higher with a worsening degree of left ventricular impairment. Increased age reduced the adverse prognosis associated with reduced left ventricular function (hazard ratios of death comparing poor left ventricular function to good left ventricular function were 2.11, 95% confidence interval 1.88-2.37 for age <65 years and 1.28, 95% confidence interval 1.20-1.36 for age ⩾85 years). Older patients had a high mortality risk even in those with good left ventricular function. Hazard ratios of mortality for ⩾85 compared to <65 years (hazard ratio = 1.00) within good, moderate and poor ejection fraction groups were 5.89, 4.86 and 3.43, respectively. Conclusions: In patients with acute coronary syndrome, clinicians should interpret the prognostic value of left ventricular function taking into account the patient's age.
Introduction
Between one-third and a half of patients who present with an acute coronary syndrome (ACS) are left with left ventricular systolic dysfunction (LVSD). 1 LVSD after ACS is a strong predictor of mortality and re-hospitalisation 2-4 even in patients who receive primary percutaneous coronary intervention 5 with the addition of left ventricular ejection fraction (LVEF) to the thrombolysis in myocardial infarction risk score improving the prediction of in-hospital death among ACS patients. 6 Rates of LVSD following ACS that have been reported through analysis of clinical trials vary from 12.6% to 36.6% depending on the mode, definition and timing of left ventricular (LV) assessment. 2, [7] [8] [9] However, these trials have highly selective cohorts in which elderly patients with multiple comorbidities may be excluded, with such older patients more likely to have LVSD. 5 The relationship between age, LVEF and mortality following ACS is itself less clear considering that increased age itself confers a poor prognosis following an ACS 10, 11 and that age-related LV remodelling may worsen outcomes. 12 Therefore, we aimed to study the prevalence of LV dysfunction in an unselected national 'real-world' ACS cohort from the myocardial ischaemia national audit project (MINAP) stratified by age, and investigated whether the prognostic significance of LV function in patients with ACS varies by age.
Methods

Study design
The MINAP was set up in England and Wales in 1999 to examine the quality of management of acute myocardial infarction. 13, 14 This national registry includes patients admitted with ACS from 230 NHS hospital trusts in England and Wales. 15 All hospitals use a standardised data collection form with prespecified definitions for all the variables. The MINAP uses a secure electronic data entry transmission and analysis system developed by the central cardiac audit database group, 16 which is part of the NHS information centre for health and social care. The current study obtained ethics approval from the faculty of medicine and health sciences research ethics committee, University of East Anglia, and the investigators had no access to patient identifiers. 17 
Cohort profile
In this paper, we included patients with an ACS admitted between January 2006 and December 2010. Patients included had received a final diagnosis of any type of ACS including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina, and these patients were followed up until the date of death or up to 31 August 2011. The final diagnosis, based on clinical assessment and investigations, was made by a senior member of the medical staff.
The original dataset consisted of 424,848 participants and data on LVEF were only available for 123,609 participants (see Supplementary Figure 1 ). A comparison of participant characteristics for those who had values for LVEF and those who did not have values for LVEF is shown in Supplementary Table 1 . Because of the degree of missing data multiple imputations by chained equations were used to account for missing data. Previous imputation analyses within MINAP have not significantly altered effect sizes 18 and the missing data are random and do not affect the validity of the analyses. 19 
Study variables
LVEF for each participant was measured by echocardiography during the index hospital admission. Good, moderate and poor LV function were defined as LVEF of ⩾50%, 30-49% and <30%, respectively.
For this analysis, age, sex, body mass index, smoking status (current smoker or ex/non-smoker), hyperlipidaemia, hypertension, comorbidities (diabetes, myocardial infarction, angina, heart failure, stroke, chronic obstructive pulmonary disease, chronic renal failure, peripheral vascular disease), previous cardiac interventions (percutaneous coronary intervention, coronary artery bypass graft), biochemical results at the time of admission with the index ACS event (quartiles of peak troponin I (cutoffs 0.6, 4.12 and 21.35 ng/ml) or T (cutoffs 0.17, 0.68 and 2.6 g/dl)), admission medications (angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, statins, aspirin, clopidogrel), diagnosis, discharge medications (as above) and use of angiography during the index admission were chosen as potentially prognostic covariates in the regression models described below. Definitions for variables are predefined by MINAP and are available on their website (http://www. ucl.ac.uk/nicor/audits/minap/dataset).
We categorised the final diagnosis into ST-segment elevation myocardial infarction and other ACSs (non-ST-segment elevation myocardial infarction, troponin negative ACS, threatened myocardial infarction and myocardial infarction (unconfirmed)).
Outcome ascertainment
MINAP is linked to the Office for National Statistics' registry and uses each patient's unique NHS number to obtain regular mortality updates. The main outcome of the analysis in this study was 30-day mortality.
Statistical methods
All analyses were performed using Stata SE, version 13.0 (Stata, College Station, TX, USA).
Multiple imputations by chained equations were used to account for missing data with 10 imputed datasets. All variables were included in the imputations model aside from those that led to failed convergence. These variables were omitted from the imputations but were kept as passive variables (renal disease, admission clopidogrel use, discharge clopidogrel use and diagnosis), which were used in the sensitivity analysis.
The frequency distribution of the baseline characteristics and 30-day mortality outcomes of patients were presented for the first imputed dataset according to the LV function. Statistical comparisons for significant baseline differences were performed using one way analysis of variance (continuous variables) or χ 2 test (categorical variables). Age was categorised into four strata (<65, 65-74, 75-84 and ⩾85 years). The prevalence of poor LV function according to age strata was evaluated graphically.
Odds ratios for 30-day mortality associated with LV function and age, adjusted for other imputed covariates, were estimated using multivariate logistic regressions. As a sensitivity analysis, the analysis was repeated including both imputed and passive covariates. Covariates for models were not selected based on significance (i.e. P value cutoff). The odds ratios for 30-day mortality with age within LV function strata, and for LV function within age strata, were estimated using a multivariate logistic regression. Formal testing of the age×LV function (binary operator to specify interactions) and age×LV function (binary operator to specify factorial interactions) interactions were explored using interaction terms that were added to these models. Addition analysis was performed to evaluate the use of beta-blockers and ACE inhibitors at discharge among patients with poor LV function according to age group.
Results
A total of 424,848 patients with ACS were recorded in the MINAP registry between 2006 and 2010. LV function data were only available for 123,609 participants. After multiple imputations, we were able to impute missing values for LV function and the imputed dataset had 414,305 participants. After controlling for potential confounders, a total of 339,887 patients was included in the regression models. The flow chart of participant inclusion is shown in Supplementary Figure 1 . Supplementary Table 2 shows the baseline characteristics of participants according to whether LV function data are available.
The characteristics of the study cohort according to LV function based on ejection fraction categories are shown in Table 1 . The majority (54%; n=223,293) of the cohort had good LV function (ejection fraction ⩾50%), while 33% (n=136,009) had moderate LV function and 13% (n=55,003) had poor LV function. Patients with poor LV function were significantly older and were more likely to have several comorbidities including hypertension, previous myocardial infarction, previous angina, heart failure, stroke, chronic obstructive pulmonary disease, renal failure, diabetes and peripheral vascular disease. For medication use before admission, there was a greater usage of medications with decreasing LV function. While the use of all medications was higher on discharge than at admission for all categories of LV function, there was a greater use of medication in patients with good LV function, with usage of medications differing significantly across categories of LV function. Crude mortality at 30 days was 7%, 9% and 17% for good, moderate and poor LV function, respectively.
The percentages of patients with poor LV function in each age groups were 8.1%, 13.1%, 17.3% and 20.1% for the age groups <65, 65-74.9, 75-84.9 and ⩾85 years, respectively ( Figure 1 ).
The crude mortality at 30 days by LVEF categories and age group is shown in Table 2 and Figure 1 . The highest mortality was observed in those with the oldest age and poorest ejection fraction. Table 2 shows the association of age group and LV function on the chances of 30-day mortality after adjustments for potential confounders. Within an age group, worsening LV function was associated with higher odds of death. For those aged <65 years, the adjusted odds of death comparing poor versus good function was 2.11 (95% confidence interval (CI) 1.88-2.37), while the corresponding results for patients in the age group ⩾85 years was 1.28 (95% CI 1.20-1.36). The odds for 30-day mortality within each LV function group attenuated with older age. When analysed within each LV function strata, in those with good LV function, there was a higher risk of death if aged ⩾85 years (odds ratio (OR) 5.89; 95% CI 5.44-6.37) compared to those aged <65 years (OR 1.00), the corresponding value for poor LV function in the ⩾85 year group was OR 3.43 (95% CI 3.11-3.78). Further analysis using age and LV interaction terms in the model only attenuated the results and all interaction terms were significant ( Table 2) .
The use of beta-blockers and ACE inhibitors at discharge among patients with poor LV function stratified by age group is shown in Table 3 . Older patients had reduced receipt of both beta-blocker and ACE inhibitors (60% and 62%, respectively, compared to 80% and 84% in the youngest age group). Sensitivity analysis was performed considering additional passive variables in the multivariate model for analysis of 30-day mortality according to age group (data not shown). In general, additional adjustments for passive variables as well as imputed variables led to similar results.
Discussion
In this study, we found that worse LV function post-ACS is associated with increased 30-day mortality, and that the association of increased mortality with worsening LV function attenuates with increased age. We showed that the prevalence of LV dysfunction in ACS patients is significant, from 8.1% in younger patients to 20.1% in older patients. Finally, we found that older ACS patients with poor LV function are less likely to receive evidence-based therapy recommended by current European Society of Cardiology and American Heart Association guidelines such as ACE inhibitors and beta-blockers.
We report for the first time that there is less adverse prognostic association between worsening LV function and mortality outcomes in older patients compared to younger patients. This novel observation may relate to a higher comorbid burden within the older cohort that would increase mortality rates irrespective of LV function. While we attempted to adjust for a wide range of comorbid conditions recorded in the MINAP dataset systematic measures of comorbidity, such as the Charlson comorbidity index that have been shown to have an independent prognostic impact in a variety of cardiovascular diseases, [20] [21] [22] [23] they are not recorded in the MINAP registry hence the possibility of residual confounding remains. For example, a recent report from the Swiss AMIS Plus registry demonstrated that close to half of all patients had at least one comorbid condition defined by the Charlson comorbidity index and that the Charlson index was an independent predictor of in-hospital and 1-year mortality. 20 Unmeasured prognostic factors such as dementia or frailty might affect both the receipt of specialist management and also eventual outcomes. Older patients with ACS are less intensively investigated and are less likely to receive evidence-based therapies recommended by guidelines that improve the prognosis of patients with poor LV function. [24] [25] [26] Possible reasons for under-treatment among the elderly include increased comorbidity and a higher risk of complications with intensive treatment. 24 There may be more uncertainty regarding the true benefits of interventions for elderly patients, as older patients are under-represented in trials and there is an absence of reliable data for such patients, which in turn leads to more conservative management that may differ from that suggested in guidelines. 27 In our contemporary ACS population, the prevalence of LV dysfunction post-ACS remains high despite the widespread population-based use of primary prevention and significant advances in ACS care over the last decade, from a high uptake of secondary prevention medication through to early precautions such as coronary intervention. Older studies that predated the use of such therapies, such as the French nationwide USIC 2000 registry, reported that 13% of participants had ejection fraction ⩽35%, 1 while in the MAGIC trial, severe LVEF (as defined by ejection fraction <30%) was present in 5.9% of participants. 7 Therefore the current data show that LVSD post-ACS remains highly prevalent.
This study has several strengths. The study represents a contemporary national cohort with a large sample size and statistical power. There is a rich case mix that allowed us to capture well the relationships between predictors (LV function and age) and outcome (30-day mortality post-ACS). We were able to control for a variety of potential confounding factors that may affect mortality, such as previous comorbidities, previous coronary interventions, acute cardiac damage markers, medications and management. Moreover, our results are from a national registry of ACS patients so the results are highly generalisable to real-world clinical practice. This cohort differs from previous work, which has focused on the impact of LVEF in specific ACS syndromes 28 or in those who underwent revascularisation only. 5, 29 Our study has some limitations. There was a large degree of missing data on LVEF so we imputed the missing data. We observed that those who did not have LVEF recorded had higher mortality rates (10% vs. 6%) and were older (mean age 69.4 vs. 68.3 years). Secondly, we were unable to determine whether recorded LV dysfunction was due to the incident infarct or was already present before presentation with ACS. Nevertheless, our objective was to examine the impact of age on the relationship between LVEF and outcome of 30-day mortality after an ACS, thus we were interested in the internal relationship between the LVEF categories and outcome post-ACS regardless of the timing of the onset of LV impairment. In addition, the primary outcome was all-cause mortality rather than cause-specific. However, it is most likely that the cause of death was related to the index ACS in the vast majority of cases. The echocardiographic evaluation for ejection fraction is not standardised across the NHS, and there may also be local variations in the proportion of patients entered into MINAP, which itself may be age biased.
Conclusions
We observed that while the prevalence of LV dysfunction increases with older age in patients who have had an ACS event, the prognostic significance of LV dysfunction in ACS diminishes with older age. We also report age-related inequalities within the UK in the management of ACS, in that older patients with ACS are less likely to receive evidence-based treatments for LV dysfunction. Finally, 50% of patients in this registry have missing LV function data despite evidence to suggest that LV function has an important prognostic impact post-ACS, and assessment of LV function in ACS is recommended by all national and international guidelines. Future studies investigating those factors that can predict outcomes more accurately in older people with ACS are also warranted for the planning of appropriate management in this age group. Efforts should also be made to understand better and address the reasons why older people are under-treated for their poor LV function after an ACS.
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